Kyverna Therapeutics (KYTX) Change in Acquisitions & Divestments (2023 - 2026)

Kyverna Therapeutics' Change in Acquisitions & Divestments history runs 4 years deep, the most recent figure standing at $65.7 million for Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 24.22% year-over-year to $65.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $384.7 million (down 2.61% YoY) and the FY2025 annual result came in at $405.7 million, up 22.46% from the prior year.
• Change in Acquisitions & Divestments was $65.7 million for Q1 2026 at Kyverna Therapeutics, down from $99.2 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $157.0 million in Q4 2024 and bottomed at $13.0 million in Q2 2024.
• A 4-year average of $77.2 million and a median of $86.7 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
• Peak annual rise in Change in Acquisitions & Divestments reached 854.62% in 2025, while the deepest fall reached 36.81% in 2025.
• Kyverna Therapeutics' Change in Acquisitions & Divestments stood at $33.0 million in 2023, then soared by 375.76% to $157.0 million in 2024, then slumped by 36.81% to $99.2 million in 2025, then plunged by 33.77% to $65.7 million in 2026.
• Business Quant data shows KYTX's Change in Acquisitions & Divestments at $65.7 million in Q1 2026, $99.2 million in Q4 2025, and $95.7 million in Q3 2025.